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ARTICLE
Synaptic density marker SV2A is reduced
in schizophrenia patients and unaffected
by antipsychotics in rats
Ellis Chika Onwordi1,2,3,4, Els F. Halff 3, Thomas Whitehurst1,3,4, Ayla Mansur5, Marie-Caroline Cotel6,
Lisa Wells7, Hannah Creeney6, David Bonsall7, Maria Rogdaki 1,2,3,4, Ekaterina Shatalina1,2,
Tiago Reis Marques1,3,4, Eugenii A. Rabiner7,8, Roger N. Gunn5,7, Sridhar Natesan 1,3,
Anthony C. Vernon 6,9 & Oliver D. Howes1,2,3,4*
Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but
this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein
2A (SV2A) levels and their relationship to symptoms and structural brain measures using
[11C]UCB-J positron emission tomography in 18 patients with schizophrenia and 18 controls.
We found significant group and group-by-region interaction effects on volume of distribution
(VT). [11C]UCB-J VT was significantly lower in the frontal and anterior cingulate cortices in
schizophrenia with large effect sizes (Cohen’s d= 0.8-0.9), but there was no significant
difference in the hippocampus. We also investigated the effects of antipsychotic drug
administration on SV2A levels in Sprague-Dawley rats using western blotting, [3H]UCB-J
autoradiography and immunostaining with confocal microscopy, finding no significant effects
on any measure. These findings indicate that there are lower synaptic terminal protein levels
in schizophrenia in vivo and that antipsychotic drug exposure is unlikely to account for them.
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Schizophrenia is a severe mental illness characterised bypositive, negative and cognitive symptoms, and is a majorcause of global disease burden1,2. Current treatments are
inadequate for many patients3,4, highlighting the need to under-
stand the pathophysiology underlying the disorder to inform drug
development5,6.
It has been hypothesised that synaptic dysfunction is central to
the pathophysiology of schizophrenia7–9. Genetic studies have
found associations between schizophrenia and variants in genes
encoding synaptic proteins10,11. A polymorphism in the synaptic
vesicle glycoprotein 2A gene (SV2A) has been associated with
increased schizophrenia risk12, although this finding has not
been replicated in genome-wide association studies. Associations
between schizophrenia and variants in genes shown to mediate
synaptic pruning in postnatal mouse neurodevelopment have
been reported13. In addition, post-mortem studies have reported
lower levels of dendritic spines14,15 and of protein and mRNA
levels of a number of synaptic markers, including synaptic vesicle
proteins such as synaptophysin and synaptopbrevin16–19, and
postsynaptic markers such as PSD-9517,20, in schizophrenia.
Synaptophysin is enriched in presynaptic nerve terminals21
where, along with synaptobrevin and SV2A, it is involved in
regulating vesicle exocytosis into synapses22,23. Recent meta-
analyses of post-mortem studies showed significantly lower
synaptophysin levels in the frontal and cingulate cortices and
hippocampus with moderate-to-large effect size8 and lower
postsynaptic element levels in schizophrenia relative to con-
trols24. Furthermore, human-derived neural cultures have shown
elevated, complement-dependent elimination of synaptic struc-
tures25, lower neurite number and neuronal connectivity26 and
synaptic vesicle release deficits27 in schizophrenia relative to
healthy controls. Further, albeit indirect, evidence for altered
synaptic function comes from in vivo neuroimaging studies
which show lower brain volumes28 and altered functional con-
nectivity in schizophrenia relative to controls29, which may reflect
altered synaptic density and/or function in schizophrenia
(although there are other potential explanations for these find-
ings). Thus, there are converging lines of evidence implicating
synaptic dysfunction in the pathophysiology of schizophrenia,
and specifically for lower levels of synaptic proteins.
However, the post-mortem findings may be affected by a
number of potential confounds, including differences in post-
mortem interval, cause of death and antipsychotic medication
exposure30. Thus, it is unknown whether synaptic protein levels
are altered in vivo. The recent development of a positron emis-
sion tomography (PET) radiotracer specific for SV2A now per-
mits in vivo investigation of presynaptic protein levels31.
Therefore, we conducted parallel clinical and preclinical studies to
address several key questions. In our clinical study, we used [11C]
UCB-J PET to test the synaptic hypothesis of schizophrenia,
anticipating that its volume of distribution (VT) would be lower
in patients with schizophrenia relative to controls in the frontal
cortex (FC), anterior cingulate cortex (ACC) and hippocampus,
regions where synaptic protein levels are lower post-mortem
in schizophrenia on meta-analysis8, and that levels would be
inversely associated with symptom severity.
Furthermore, we performed an exploratory analysis to test
whether effects are generalised to other brain regions (occipital,
parietal and temporal lobes, dorsolateral prefrontal cortex,
thalamus and amygdala) where structural and/or functional
alterations have been identified in schizophrenia using in vivo
neuroimaging28,32,33, and we calculated distribution volume ratio
(DVR) in each region of interest (ROI), using the centrum
semiovale as a pseudoreference region for estimates of non-
displaceable binding of [11C]UCB-J31. In our preclinical study,
we used a well-validated rat model of clinically comparable
antipsychotic drug exposure to investigate whether chronic
antipsychotic drug exposure at clinically relevant doses alters
SV2A protein levels and/or specific binding in drug-naïve
rats, predicting there would be no effect given the evidence that
chronic haloperidol (HAL) exposure does not impact on synap-
tophysin levels in the rat FC34,35. We report here the first direct
in vivo evidence for synaptic dysfunction in schizophrenia toge-
ther with results from preclinical experiments suggesting that this
dysfunction is not explained by antipsychotic drug exposure at
clinically relevant doses.
Results
Thirty-six volunteers (n= 18 with schizophrenia [SCZ, 15 male
and 3 female] and 18 healthy volunteers [HV, 15 male and 3
female]) completed the clinical study. The groups were not sig-
nificantly different in age (mean [standard error of the mean,
SEM] years of SCZ group= 41.5 [2.7]; HV group= 38.7 [3.1];
Kolmogorov–Smirnov D= 0.28, p= 0.49), activity injected
(mean [SEM] MBq in SCZ= 237.4 [11.76]; HV= 257.1 [6.49];
Kolmogorov–Smirnov D= 0.28, p= 0.49) or [11C]UCB-J
plasma-free fraction (mean [SEM] fp in SCZ = 0.24 [0.005];
HV= 0.25 [0.006]; t= 0.63, df= 34, p= 0.53).
All volunteers with schizophrenia were on antipsychotic med-
ication (mean [SEM] chlorpromazine-equivalent dose= 443.5
[89.6] mg/day, Supplementary Table 1). None of the volunteers
with schizophrenia had co-morbid DSM-5 psychiatric diagnoses.
[11C]UCB-J VT across groups in a priori ROIs. There was a
significant effect of group (two-way ANOVA: F1,34= 6.170, p=
0.02) and ROI (F2,68= 426.0, p < 0.0001) on [11C]UCB-J VT.
Furthermore, there was a significant group-by-ROI interaction
effect on [11C]UCB-J VT (F2,68= 7.472, p= 0.001). Post-hoc
analyses with false-discovery rate (FDR) adjustment revealed that
mean [SEM] [11C]UCB-J VT (ml/cm3) was significantly reduced
in the SCZ relative to the HV group in the frontal cortex, FC
(SCZ= 16.93 [0.80]; HV= 19.50 [0.64]; t= 2.51, df= 34.0, p=
0.03), and in the anterior cingulate cortex, ACC (SCZ= 19.55
[0.75]; HV= 22.49 [0.72]; t= 2.83, df= 34.0, p= 0.02), with
large effect sizes (Cohen’s d= 0.8 and 0.9, respectively), as shown
in Fig. 1. However, there was no significant difference between
groups in [11C]UCB-J VT in the hippocampus (mean [SEM] VT
SCZ= 14.09 [0.59]; HV= 15.44 [0.50]; t= 1.75, df= 34.0, p=
0.09, Cohen’s d= 0.6). Figure 2 shows mean parametric [11C]
UCB-J VT brain images for the SCZ and HV groups.
Relationship between [11C]UCB-J VT and grey matter volume.
There was a significant effect of ROI (two-way ANOVA: F2,68=
1835, p < 0.0001) but not of group (F1,34= 2.10, p= 0.16) or
group-by-ROI interaction effect (F2,68= 1.85, p= 0.16), on cor-
rected grey matter volume (GMV) (Supplementary Fig. 1). There
were no significant associations between [11C]UCB-J VT and
corrected GMV in any of the ROIs, neither in the combined
sample nor in HV nor SCZ groups analysed separately (Table 1).
Relationship between [11C]UCB-J VT and clinical variables.
There were no significant relationships between [11C]UCB-J VT
in the FC, ACC or hippocampus and chlorpromazine-equivalent
dose, Positive and Negative Syndrome Scale (PANSS) total,
PANSS-positive, PANSS-negative or PANSS general scores or
duration of illness (Table 2). We conducted exploratory analyses
to explore the potential influence of smoking, concomitant
medication and clozapine treatment on VT. These showed no
significant effect of these variables on VT (see Supplementary
Notes 1, 2 and 3).
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Exploratory analysis of [11C]UCB-J VT in other regions. There
was a significant effect of group (two-way ANOVA: F1,34= 6.362,
p= 0.02) and ROI (F5,170= 125.2, p < 0.0001) on [11C]UCB-J VT.
There was no significant group-by-ROI interaction effect on [11C]
UCB-J VT (F5,170= 1.148, p= 0.34). Post-hoc analyses with FDR
adjustment revealed that mean [SEM] [11C]UCB-J VT (ml/cm3)
was significantly reduced in the SCZ relative to the HV group in
the dorsolateral prefrontal cortex (SCZ= 17.20 [0.80]; HV=
19.83 [0.59]; t= 2.63, df= 34.0, p= 0.03, Cohen’s d= 0.9);
temporal lobe (SCZ= 18.05 [0.68]; HV= 20.64 [0.68]; t= 2.69,
df= 34.0, p= 0.03, Cohen’s d= 0.9); occipital lobe (SCZ= 16.98
[0.64]; HV= 19.25 [0.73]; t= 2.34, df= 34.0, p= 0.04, Cohen’s
d= 0.8); parietal lobe (SCZ= 17.25 [0.70]; HV= 19.42 [0.75];
t= 2.12, df= 34.0, p= 0.04, Cohen’s d= 0.7), thalamus (SCZ=
13.12 [0.54]; HV= 15.17 [0.62]; t= 2.51, df= 34.0, p= 0.03,
Cohen’s d= 0.8) and amygdala (SCZ= 17.09 [0.64]; HV= 18.78
[0.64]; t= 2.09, df= 34.0, p= 0.03, Cohen’s d= 0.7; Supple-
mentary Fig. 2).
[11C]UCB-J VT across groups in centrum semiovale.
The groups were not significantly different in [11C]UCB-J VT
(ml/cm3) in the centrum semiovale (mean [SEM] VT (ml/cm3) in
SCZ group= 6.06 [0.34], HV group= 5.66 [0.14], t= 1.10, df=
34, p= 0.28 [two-tailed independent samples t-test]).
[11C]UCB-J DVR across groups in a priori ROIs. Figure 3
shows the DVRs by group. There was a significant effect of group
(two-way ANOVA: F1,34= 8.1, p= 0.007) and of ROI (F2,68=
510.9, p < 0.0001) on [11C]UCB-J DVR. Furthermore, there was a
significant group-by-ROI interaction effect on [11C]UCB-J DVR
(F2,68= 7.97, p= 0.0008). Post-hoc analyses with FDR adjust-
ment revealed that mean (SEM) [11C]UCB-J DVR was sig-
nificantly lower in the FC (SCZ= 2.93 [0.17]; HV= 3.48 [0.09];
t= 2.89, df= 34.0, p= 0.01, Cohen’s d= 1.0), ACC (SCZ= 3.39
[0.17]; HV= 3.99 [0.09]; t= 3.05, df= 34.0, p= 0.01, Cohen’s
d= 1.0) and the hippocampus (SCZ= 2.40 [0.12]; HV= 2.74
[0.07]; t= 2.32, df= 34.0, p= 0.03, Cohen’s d= 0.8; Fig. 3).
[11C]UCB-J DVR across groups in exploratory ROIs. There was
a significant effect of group (two-way ANOVA: F1,34= 8.47, p=
0.0063) and of ROI (F5,170= 153.4, p < 0.0001) on [11C]UCB-J
DVR. There was no significant group-by-ROI interaction effect
on [11C]UCB-J DVR (F5,170= 1.75, p= 0.13). Post-hoc analyses
with FDR adjustment revealed that mean [SEM] [11C]UCB-J
DVR was significantly lower in the occipital lobe (SCZ= 2.93
[0.15]; HV= 3.43 [0.10]; t= 2.72, df= 34.0, p= 0.02, Cohen’s
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Fig. 2 Mean parametric [11C]UCB-J VT images from healthy volunteer (HV) and schizophrenia (SCZ) groups. Colour bar indicates [11C]UCB-J VT.
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d= 0.9); parietal lobe (SCZ= 2.97 [0.16]; HV= 3.46 [0.11]; t=
2.61, df= 34.0, p= 0.02, Cohen’s d= 0.9); temporal lobe (SCZ=
3.10 [0.15]; HV= 3.69 [0.09]; t= 3.36, df= 34.0, p= 0.01,
Cohen’s d= 1.1); dorsolateral prefrontal cortex (SCZ= 2.99
[0.17]; HV= 3.53 [0.09]; t= 2.89, df= 34.0, p= 0.02, Cohen’s
d= 1.0); thalamus (SCZ= 2.28 [0.13]; HV= 2.74 [0.10]; t= 2.77,
df= 34.0, p= 0.02, Cohen’s d= 0.9); and amygdala (SCZ= 2.95
[0.14]; HV= 3.35 [0.08]; t= 2.54, df= 34.0, p= 0.02, Cohen’s
d= 0.8, Supplementary Fig. 3).
Chronic antipsychotic drug exposure in rats. Administration
of the antipsychotic drugs haloperidol (HAL) and olanzapine
(OLZ) by osmotic minipumps for 28 days achieved clinically
relevant plasma levels in rats, comparable with previous studies
(Table 3)36–38.
SV2A protein levels in the rat frontal cortex. We first examined
total SV2A protein levels in synaptosomes isolated from rat
frontal cortex (FC) samples (comprising both the prefrontal and
anterior cingulate cortices [PFC and ACC]) using western blot-
ting. This was based on the finding that regional protein levels of
SV2A are highly correlated with in vivo specific binding of [11C]
UCB-J31 and the main finding of our clinical study that [11C]
UCB-J binding is significantly reduced in the frontal and anterior
cingulate cortices of volunteers with schizophrenia who were
receiving antipsychotic medication, as compared to controls. A
protein band of ~100 kDa corresponding to SV2A was observed
using synaptosomes prepared from rat FC (Fig. 4a). The primary
antibody used has been validated previously both in SV2A knock-
out mice and with blocking peptides39. Chronic exposure for
28 days to two different doses of HAL did not significantly affect
the protein levels of SV2A (relative to GAPDH) in the rat FC as
Table 1 Associations between corrected grey matter volume and [11C]UCB-J VT.
Full sample (n= 36)
correlation coefficient
p value HV (n= 18) correlation
coefficient
p value SCZ (n= 18) correlation
coefficient
p value
Hippocampus 0.21 0.21 0.06 0.82 0.26 0.30
Frontal cortex 0.20 0.25 0.01 0.95 0.13 0.61
Anterior cingulate cortex 0.19 0.26 −0.005 0.99 0.32 0.20
Relationships were explored in the hippocampus, frontal cortex and anterior cingulate cortex, in the full sample and in the separated schizophrenia (SCZ) and healthy volunteer (HV) groups. All
correlation coefficients reported are Pearson product-moment correlation coefficients, except where use of italics signifies Spearman’s rank correlation coefficients for nonparametric data. There were no
significant associations between grey matter volume and [11C]UCB-J VT in any of the regions of interest
Table 2 Associations between clinical variables and [11C]UCB-J VT.
PANSS total
correlation
coefficient
p Value PANSS-
positive
correlation
coefficient
p Value PANSS-
negative
correlation
coefficient
p Value PANSS
general
correlation
coefficient
p Value Chlorpromazine-
equivalent dose
correlation
coefficient
p Value Duration of
illness
correlation
coefficient
p Value
Hippocampus −0.09 0.71 −0.11 0.69 −0.10 0.72 −0.04 0.89 −0.36 0.14 −0.15 0.56
Frontal cortex −0.13 0.61 −0.07 0.80 −0.09 0.73 −0.14 0.60 −0.34 0.17 −0.29 0.24
Anterior
cingulate cortex
−0.04 0.87 0.02 0.93 −0.09 0.73 −0.04 0.89 −0.32 0.20 −0.33 0.17
Associations between PANSS scores (total and positive, negative and general subscale scores), chlorpromazine-equivalent dose and duration of illness and [11C]UCB-J VT were explored in the
schizophrenia group (n= 18) in the hippocampus, frontal cortex and anterior cingulate cortex. There were no significant associations between PANSS scores, chlorpromazine-equivalent dose or duration
of illness and [11C]UCB-J VT in any of the regions of interest. All correlation coefficients reported are Pearson product–moment correlation coefficients, except where use of italics signifies Spearman’s
rank correlation coefficients for nonparametric data
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Fig. 3 Regional mean [11C]UCB-J distribution volume ratio (DVR) group.
Grey bars depict regional mean DVR in the healthy volunteer (HV) group,
and triangles represent individual HV DVR (n= 18). Hollow bars depict
mean DVR in the schizophrenia (SCZ) group, and circles indicate individual
SCZ patient DVR (n= 18). FDR-adjusted p values from post-hoc t-tests are
reported here. [11C]UCB-J DVR was significantly reduced with large effect
sizes (Cohen’s d > 0.8) in the SCZ compared to the HV group in the frontal
cortex, anterior cingulate cortex (ACC) and the hippocampus. Error bars
indicate standard error of the mean.
Table 3 Plasma levels of haloperidol (HAL) and olanzapine
(OLZ) in treated rats.
Cohort 0.5 mg/kg/
day HAL
2mg/kg/
day HAL
7.5 mg/kg/
day OLZ
1 2.96 ± 0.52 ng/ml 12.2 ± 1.96 ng/ml n.a.
2 3.03 ± 0.94 ng/ml n.a. n.a.
3. n.a. n.a. 15.5 ± 5.54 ng/ml
“n.a.” means “not applicable”
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compared to vehicle controls (Kruskal–Wallis: p= 0.71); Fig. 4b.
Furthermore, analyses of uncorrected SV2A protein levels in the
rat FC showed no significant effect of HAL (Supplementary
Note 4). See Supplementary Fig. 4 for unprocessed western blot
images of SV2A and GAPDH protein levels in synaptosome
fractions purified from the rat FC.
[3H]UCB-J specific binding in the rat FC. Using brain tissue
from the opposite hemisphere of a subset of the animals (n= 15)
in which western blots were carried out, we next measured the
specific binding of [3H]UCB-J using ex vivo autoradiography in
the PFC and ACC. In agreement with prior in vivo studies31
using [11C]UCB-J, the specific binding of [3H]UCB-J is clearly
higher in grey as compared to white matter (Fig. 4c). There were,
however, no statistically significant effects of HAL administration
on [3H]UCB-J specific binding (two-way ANOVA: F2,12= 1.451,
p= 0.27); Fig. 4d.
Cellular localisation of SV2A in the rat FC. To confirm the
aforementioned results and evaluate the cellular localisation of
SV2A, fluorescence immunohistochemistry was carried out on
fixed brain tissue from a second cohort of rats chronically exposed
to either vehicle or HAL (0.5 mg/kg/day) for 28 days. Consistent
with the ex vivo autoradiography and prior in vivo work31, SV2A
a c d
b
e f
g
SV2A
150
100
kD
a
37 GAPDH
ACC
STR
WM
H
al
op
er
id
ol
Ve
hi
cl
e
Total intensity Background correction
Pr
ef
ro
nt
al
 c
or
te
x 
(P
FC
)
Total binding Non-specific binding
An
te
rio
r c
in
gu
la
te
 c
or
te
x 
(A
CC
)
58.8
17.0
11.6
8.4
6.2
4.4
3.0
1.8
1.1
0.6
0.4
0.2
0.1
0
–0.2
–0.3
–0.5
Bi
nd
in
g 
(x1
03
 
fm
ol
/m
g 
tis
su
e)
WM
WM
High-HAL
Low-HAL
Vehicle
0.5
5000
4000
3000
0
5000
4000
3000
0
20
15
10
5
Fl
uo
re
sc
en
ce
 in
te
ns
ity
/µ
m
2
0
PFC
Vehicle Haloperidol
ACC
Sp
ec
ific
 b
in
di
ng
(fm
ol/
mg
 tis
su
e)
Sp
ec
ific
 b
in
di
ng
(fm
ol/
mg
 tis
su
e)
0.4
0.3
0.2
0.1S
V2
A/
G
AP
DH
0.0
Vehicle Low-HAL High-HAL
Vehicle Low-HAL High-HAL
Vehicle Low-HAL High-HAL
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levels in synaptosomes isolated from the FC. b Quantification of total SV2A levels on western blot, normalised to GAPDH, showed no significant changes
upon chronic haloperidol treatment (Kruskal–Wallis test, p= 0.71). c Autoradiography images of brain sections incubated with 12.5 nM [3H]UCB-J in
absence (left) or presence (right) of levetiracetam (a drug that binds to SV2A). Black boxes indicate which ROI was selected to measure tracer binding in
the prefrontal cortex, PFC (top), or anterior cingulate cortex, ACC (bottom). WM, white matter. Colour bar indicates [3H]UCB-J binding levels. Scale bar,
1 mm d Quantification of [3H]UCB-J binding in PFC (top) and ACC (bottom), indicating no significant changes upon chronic haloperidol treatment (two-
way ANOVA, F2,12= 1.451, p= 0.27). e Top: schematic of brain section at Bregma 1.1 mm. Bottom: low magnification fluorescent image of a rat brain
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magnification confocal images of brain sections from vehicle- (top) or haloperidol- (bottom) treated animals, showing punctate immunostaining for SV2A.
Both raw images (left hand side) as well as background corrected images (right hand side) are shown. White arrows indicate a lack of SV2A punctae in the
cell body; yellow arrows indicate examples of presynaptic terminals at perisomatic synapses and proximal dendrites. Scale bar, 10 µm (large field of view)
or 4 µm (zoomed insets). g Quantification of background corrected SV2A intensity values. There were no significant differences in SV2A immunostaining
intensity between vehicle- and haloperidol-treated groups (two-way ANOVA with Bonferroni’s multiple comparison correction, F1,20= 0.1412, p= 0.71).
Error bars indicate standard error of the mean.
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staining was high in grey matter, but negligible in white matter
(Fig. 4e). SV2A staining was also absent in neuronal cell bodies
(white arrows in Fig. 4f) but high at the perisomatic region
(including the border of a proximal dendrite, yellow arrows in
Fig. 4f). Total SV2A intensity after background correction varied
significantly by region (two-way ANOVA: F1,20= 5.112 p=
0.035), but did so comparably between groups with no significant
effect of treatment (F1,20= 0.1412, p= 0.71) or treatment-by-
region interaction (F1,20= 0.2513, p= 0.62); Fig. 4g.
Finally, to test whether the findings with HAL can be
generalised to other antipsychotic drugs, we explored the effects
of chronic OLZ administration on SV2A immunostaining
intensity in the rat PFC and ACC (Supplementary Fig. 5). In
agreement with the results from HAL treatment, chronic
administration of OLZ also did not induce any significant
differences in SV2A immunostaining intensity (two-way ANOVA;
effect of treatment: F1,14= 0.0018, p= 0.97; region: F1,14= 2.01,
p= 0.18; treatment-by-region interaction: F1,14= 1.87, p= 0.19).
Discussion
Our main finding is that [11C]UCB-J volume of distribution
(VT), an in vivo marker of synaptic vesicle glycoprotein 2A
levels and proxy marker of synaptic nerve terminal density, is
significantly lower in schizophrenia relative to controls in the
FC and ACC with large effect sizes (Cohen’s d= 0.8–0.9).
Furthermore, we did not detect a significant effect of a 28-day
antipsychotic drug exposure at clinically comparable doses on
either SV2A protein levels or [3H]UCB-J specific binding in the
PFC or ACC of the naïve rat brain. Our results confirm and
extend post-mortem evidence for lower levels of presynaptic
protein markers in schizophrenia8 by demonstrating lower
levels of SV2A in the FC and ACC in vivo in schizophrenia for
the first time.
Moreover, in contrast to post-mortem studies, we were able to
examine multiple regions in each individual, and find evidence for
regional differences in the magnitude of effects, given the finding
of a significant group-by-ROI interaction effect. We found lower
[11C]UCB-J VT across multiple brain regions, but also evidence
that frontal cortical regions may be more affected than hippo-
campus. The results were largely the same when using an alter-
native outcome measure, the DVR, which uses a brain region, the
centrum semiovale, that is thought to be largely devoid of SV2A as
a reference region to adjust for non-specific binding31. The one
exception was the hippocampus, where DVR was significantly
lower in the schizophrenia group relative to controls, albeit the
effect size in the hippocampus was not as large as those in the
other regions. This difference between the VT and DVR results for
the hippocampus may reflect the fact that DVR values show lower
variability and so are likely to have greater sensitivity to detect
group differences40, and our study lacked sufficient power to
detect smaller effect size differences in hippocampal VT. Thus, our
finding that effects are less marked in the hippocampus relative to
the FC warrants confirmation in future studies.
The exploratory analysis of additional brain regions showed
significantly lower SV2A levels in the dorsolateral prefrontal and
temporal cortices and occipital lobe in schizophrenia, consistent
with other evidence implicating synaptic pathology in these regions
in schizophrenia14,15,19,41,42, but not consistent with meta-analytic
post-mortem findings for synaptophysin in these regions8. The
discrepancies between our findings and the post-mortem findings
in these regions may reflect the fact we measured SV2A binding
whilst the post-mortem studies measured other synaptic proteins,
or could reflect the fact that our sample was younger and had a
shorter illness duration than most of the patients in the post-
mortem analyses, and/or the influence of post-mortem interval on
synaptic protein levels8. Our null findings in our preclinical study
are in agreement with, and extend, previous preclinical findings in
which chronic HAL exposure had no statistically significant effect
on synaptophysin protein levels in the rat or nonhuman primate
cortex34,35,43, by showing HAL did not alter the levels or specific
binding of another presynaptic protein, SV2A.
A strength of our clinical study is the use of an in vivo measure of
synaptic protein levels, which avoids some potential confounds such
as agonal status and cause of death that may affect brain pH and
protein and mRNA levels in post-mortem approaches30. Moreover,
[11C]UCB-J has shown good test–retest reproducibility, indicating it
is a reliable imaging tool44. Our main outcome measure, VT, is the
concentration of the radioligand in the tissue target region relative
to that in the plasma at equilibrium and, thus, is proportional to
[11C]UCB-J binding to the target in the ROI45. It is important to
recognise that VT includes both the concentration of radioligand
specifically bound to SV2A and the non-specific uptake (that is,
non-specifically bound and free radioligand concentrations).
Approximately 80% of [11C]UCB-J VT in nonhuman primate grey
matter regions is accounted for by specific binding46,47, suggesting
the lower values in schizophrenia are likely to be predominantly
accounted for by differences in specific binding. To investigate if
non-specific uptake was influencing our findings, we repeated the
analysis using DVR as the outcome, which uses the centrum
semiovale as a pseudoreference region to adjust for non-specific
uptake in brain. The centrum semiovale is a white matter region
that is largely devoid of SV2A and displays very low uptake of [11C]
UCB-J31,44,48. Nevertheless, there is a small amount of displacement
of [11C]UCB-J uptake in the centrum semiovale by a drug, leve-
tiracetam, that is selective for SV2A31, suggesting that there is a
degree of specific binding in the centrum semiovale. Blocking stu-
dies indicate that this is about 8% of the specific binding in grey
matter, leading to a slight underestimation of specific binding in
grey matter, and white matter may not be an optimal reference
region because its tissue composition is different from grey mat-
ter49. Notwithstanding this, our DVR results indicate that the lower
[11C]UCB-J VT values in schizophrenia likely reflect lower specific
binding to SV2A.
Lower GMVs are reported in the FC and ACC in schizo-
phrenia28, indicating that partial volume effects could contribute to
our findings. That we found no significant alterations in regional
corrected GMV likely reflects the small-to-medium effect size
reductions in volume relative to healthy controls and heterogeneity
in the alterations between patients28, and crucially limits con-
founding partial volume effects. Furthermore, we did not detect a
significant association between regional corrected GMV and
regional [11C]UCB-J VT, suggesting that GMVs are unlikely to
account for our findings. Interestingly, this also raises the question
as to what underlies the widely reported lower GMVs in schizo-
phrenia. In our clinical study, the volunteers are mostly male (n=
15 of 18 per group), which may limit generalisations to female
patients. However, previous work has not found an effect of sex on
[11C]UCB-J VT50,51. Six patients were taking clozapine (Supple-
mentary Table 1), which, as this is generally reserved for patients
whose illness is antipsychotic treatment resistant52, could indicate
that a third of our sample met criteria for treatment-resistant
schizophrenia, although this was not formally assessed. Population
studies indicate that antipsychotic treatment resistance is seen
in about one-third of chronic and about 20% of first-episode
patients53,54, indicating our sample is representative of chronic
schizophrenia but less representative of first-episode patients in this
respect. We did not find a significant difference in VT between
clozapine-treated and non-clozapine-treated patients (Supplemen-
tary Note 3), although, as the study was not designed to test dif-
ferences between these groups, it would be interesting to test this in
a further study.
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It is important to note that increased vesicle number and
vesicle clustering effects have been reported in schizophrenia
using light microscopy in post-mortem samples55,56. However, it
is not obvious how such effects would affect our results, given that
they do not necessitate alterations in SV2A protein availability
and the evidence that synaptic vesicle clustering and disintegra-
tion are post-mortem effects57.
Additional methodological limitations were that all volunteers
in the schizophrenia group were taking antipsychotic drug
treatment and there were significantly more smokers in the
schizophrenia than the control group (Supplementary Table 1;
Supplementary Note 1; Supplementary Data 1). Furthermore,
although we excluded any volunteers taking any drugs known to
bind to SV2A, a small number of patients were taking con-
comitant psychotropics on top of their antipsychotic medication
(Supplementary Note 2; Supplementary Data 1). However, we
found no significant association between current antipsychotic
dose and [11C]UCB-J VT, and no indication that smoking or
concomitant psychotropic treatment influenced VT (Supplemen-
tary Notes 1 and 2). Moreover, a previous study has reported no
effect of smoking on [11C]UCB-J VT51.
Furthermore, data in our preclinical study show that chronic
exposure to the antipsychotic drug haloperidol has no significant
effects on either SV2A protein levels (as measured by western blot
and immunofluorescence), or the specific binding of [3H]UCB-J,
a comparable measure to our main neuroimaging end-point in
our clinical study. In addition, our data show that SV2A protein
levels measured by immunofluorescence are not altered by
chronic administration of olanzapine. Strengths of our preclinical
study include the combination of three independent but com-
plementary measures of SV2A, and the use of a previously vali-
dated model of chronic antipsychotic drug exposure that
recapitulates clinic-like plasma levels and pharmacokinetics36–38.
Antipsychotic drugs accumulate in synaptic vesicles and are
secreted upon exocytosis, resulting in increased extracellular drug
concentrations during neuronal activity and dose-dependent
inhibition of electrically stimulated synaptic vesicle exocytosis58,
which could theoretically affect [11C]UCB-J binding. At least
14 days of HAL treatment, using an identical drug-delivery sys-
tem to our own work, appears to be necessary for elevated
extracellular HAL levels following high potassium stimulation58.
In the current study, we exposed rats to an identical HAL dose as
used in this study, as well as a higher dose of 2 mg/kg/day, for
double that time, but did not find any change in SV2A protein or
specific binding of [3H]UCB-J. Therefore, whilst additional
experiments are required to definitively rule out any effect of
antipsychotic-induced vesicle exocytosis on SV2A protein or
ligand binding, the aforementioned findings suggest this is unli-
kely to be the case.
In agreement with the absence of effect of drug administration on
SV2A levels detected here, previous studies from our group have
consistently found no differences between vehicle and HAL or OLZ
exposure in their effects either on rat brain anatomy or at the
cellular level38,59–61. Notably, our rats were otherwise healthy and
so disorder-by-drug interactions were not captured. It has been
found previously that, in a rodent model using phencyclidine
exposure to recapitulate dopaminergic and cognitive alterations
associated with schizophrenia, OLZ treatment rescued exposure-
associated synapse loss in the prefrontal cortex but did not affect
synaptic density in healthy animals62. However, a previous study
found no effect of chronic HAL on synaptophysin levels in the
hippocampus or FC of a rodent model based on the glutamatergic
hypothesis of schizophrenia63. We examined the effects of a 28-day
exposure (roughly equivalent to 2.4 human years64, although this is
a very simplified model). Most of the volunteers with schizophrenia
in our study had taken antipsychotic drugs longer than this. Whilst
the null results in our preclinical study are consistent with those of
others examining the effect of HAL on presynaptic protein levels
using a similar duration of exposure34,35,43, our study was not
powered to detect small effects so we cannot exclude the possibility
that there is a small effect and/or that a longer duration of anti-
psychotic drug exposure may affect SV2A protein levels or specific
binding. Notwithstanding this, our findings from our clinical and
preclinical studies suggest that antipsychotic medication exposure is
unlikely to account for the lower [11C]UCB-J binding in schizo-
phrenia patients. Nonetheless, future studies investigating SV2A in
untreated, first-episode psychosis patients and controlling for
smoking would be useful to test this further, and to determine if
SV2A changes occur early in the course of illness. It is also
important to recognise that our study is only powered to detect a
strong relationship with symptoms, so it remains possible that there
is a relationship between VT and symptoms. Longitudinal studies
and larger samples are needed to test the time course of alterations
and their relationship with symptoms further.
Non-human primate studies show a strong positive relation-
ship between [11C]UCB-J VT and in vitro SV2A levels determined
using western blots (r > 0.8) and binding assays (r > 0.9)31.
Moreover, displacement studies31,47 using levetiracetam, a drug
that binds selectively to SV2A65, show the [11C]UCB-J signal is
blocked substantially, indicating specificity to SV2A. This evi-
dence indicates that [11C]UCB-J is a specific marker of SV2A
levels, and thus that SV2A levels are reduced in schizophrenia.
SV2A, one of three isoforms of SV2, is ubiquitously expressed
throughout the brain and is present in GABAergic and gluta-
matergic presynaptic nerve terminals66. Furthermore, SV2A
levels are strongly, positively correlated with synaptophysin levels
in the brain (r > 0.95)31, which is reduced in disorders associated
with synaptic loss67 and is widely used as a marker of synaptic
density. With five copies per synaptic vesicle, SV2 shows much
lower variability in this regard than synaptophysin68. [11C]UCB-J
PET has demonstrated sensitivity to synaptic reductions in
temporal lobe epilepsy and Alzheimer’s disease31,69, and has
provided evidence consistent with synaptic alterations in affective
disorders51. Thus, the lower [11C]UCB-J uptake we observe in
schizophrenia could be due either to a reduction in SV2A levels
specifically, or a reduction in nerve terminal number manifest as
decreased levels of SV2A and other synaptic protein levels. SV2A
transcript levels have been reported to be lower in the cerebellar
cortex in schizophrenia post-mortem70 but, to our knowledge,
there have not been studies in the FC, ACC or hippocampus, and
this does not preclude a reduction in synaptic terminal number as
well. Moreover, when our findings are taken with evidence of
reductions in other synaptic vesicle proteins8,16,17,41,71, cortical
neuropil72, cortical dendritic spine density14,15,42 and spine
plasticity73 coupled with unaltered neuronal numbers in schizo-
phrenia74, the most parsimonious explanation is that they reflect
lower synaptic terminal density. A reduction in synaptic term-
inals could be due to a developmental failure to form synapses
and/or excessive synaptic pruning in schizophrenia7,9, potentially
linked to microglial-mediated mechanisms13,25,75.
Notwithstanding the discussion above on whether our findings
reflect a specific loss of SV2A or indicate lower synaptic terminal
levels, lower SV2A levels may also have functional consequences.
SV2A plays a key role in neurotransmitter exocytosis from vesicles
into the synaptic cleft23. SV2A knock-out in mice results in deficits
in action potential-induced GABAergic neurotransmission76, and
pharmacological modulation of SV2A function alters post-synaptic
excitatory and inhibitory potentials77. Moreover, SV2A levels in the
dorsolateral prefrontal cortex indexed using [11C]UCB-J are nega-
tively associated with functional connectivity between that region
and the posterior cingulate cortex in patients with affective
disorders51. Thus, lower SV2A levels could have functional
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consequences, theoretically altering excitatory–inhibitory balance,
thereby impairing interactions between neuronal systems and
contributing consequently to the dysconnectivity observed in schi-
zophrenia78, although this requires testing.
Finally, our finding that there is no association between
symptom severity and [11C]UCB-J VT could suggest that synaptic
alterations occur early in the course of the illness, consistent with
models that early neurodevelopment is disrupted in schizo-
phrenia with subsequent changes in dopamine and other neu-
rotransmitter systems leading to psychotic symptoms75,79.
In conclusion, SV2A levels are significantly lower in the FC and
ACC in schizophrenia, and antipsychotic drug exposure at clinically
relevant doses does not significantly alter SV2A levels or [3H]UCB-
J-specific binding in the prefrontal and cingulate cortices of naïve
rats. These findings indicate that synaptic alterations occurs in vivo
in schizophrenia, and lower SV2A levels are unlikely to be directly
accounted for by antipsychotic drug treatment.
Methods
Schizophrenia patient and healthy volunteer recruitment. The study protocol
(Integrated Research Application System reference number: 209761) was approved
by the London-West London & GTAC Research Ethics Committee (study refer-
ence: 16/LO/1941) and approval to administer radioactive material was obtained
from the Administration of Radioactive Substances Advisory Committee (ARSAC,
UK). All human participants provided written, informed consent before partici-
pating in the study, which was conducted in accordance with the Declaration of
Helsinki.
We recruited 18 individuals with a DSM-5 diagnosis of schizophrenia from
community mental health services in London. Eighteen healthy volunteers were
recruited through public advertisement. Inclusion criteria for all volunteers were:
aged between 18 and 65 years old, demonstrated capacity to consent, and had a
normal blood coagulation test.
In addition, individuals with schizophrenia were required to meet DSM-5
criteria for a diagnosis of schizophrenia and to have had no changes in treatment
for at least 4 weeks prior to the screening visit; and healthy volunteers were
required to have no history of a current or lifetime diagnosis of a mental disorder
or family history of schizophrenia.
Exclusion criteria for all volunteers were: history of neurological disorder, head
trauma resulting in a loss of consciousness, drug or alcohol dependence (except for
nicotine dependence); significant medical disorder; taking a drug known to interact
with SV2A (including levetiracetam, brivaracetam, loratadine or quinine);80 or
contraindications to imaging.
Clinical assessments. Volunteers with schizophrenia underwent a psychiatric
symptom assessment by a psychiatrist using the PANSS81 to assess symptom
severity and the Structured Clinical Interview for DSM-5 to confirm the diagnosis
and to assess for psychiatric co-morbidities. Healthy volunteers were screened with
the Structured Clinical Interview for DSM-5 to exclude any psychiatric illness. The
healthy volunteers were screened to exclude any family history of psychosis.
Magnetic resonance imaging. All subjects underwent structural magnetic reso-
nance imaging (MRI) to facilitate the anatomical delineation of ROIs. For all
patients and 16 of the healthy volunteers, T1-weighted three-dimension
magnetisation-prepared rapid acquisition gradient echo (MPRAGE) images were
acquired on a Siemens Magnetom Prisma 3T scanner (Siemens, Erlangen, Ger-
many) according to the following parameters: repetition time= 2300.0 ms, echo
time= 2.28 ms, flip angle= 9°, field of view (FOV)= 256 × 256 mm, 176 sagittal
slices of 1-mm thickness, distance factor= 50%, voxel size= 1.0 × 1.0 × 1.0 mm.
For two healthy volunteers, T1-weighted three-dimension MPRAGE images were
acquired on a Siemens 3T Trio clinical MRI scanner (Siemens Healthineers,
Erlangen, Germany) with the following parameters: repetition time= 2300.0 ms,
echo time= 2.98 ms, flip angle= 9°, FOV= 256 × 256 mm, 160 sagittal slices of 1-
mm thickness, distance factor= 50%, voxel size= 1.0 × 1.0 × 1.0 mm.
PET imaging. All participants underwent a PET scan with [11C]UCB-J, a radi-
oligand specific for SV2A31,47. Each subject had a CT scan for attenuation cor-
rection purposes 2 min prior to the injection of radiotracer. The study physician
administered a microdose of [¹¹C]UCB-J (target activity approximately 300MBq)
via an intravenous cannula as a smooth bolus injection over 20 s. PET data were
acquired for 90 min using a Biograph 6 HiRez PET-CT scanner (Siemens, Erlan-
gen, Germany). Arterial blood was collected throughout the PET scan unilaterally
via the radial artery to measure the arterial input function.
Arterial blood sampling. Whole-blood activity was measured using a continuous
automatic blood sampling system (Allogg AB, Mariefred, Sweden). Discrete
samples were taken at 10, 15, 20, 25, 30, 40, 50, 60, 70, 80 and 90 min after tracer
injection. Total radioactivity concentration was evaluated in blood and plasma
using a Perkin Elmer 1470 10-well gamma counter. Discrete blood samples were
used to determine the plasma radioactivity fraction constituted by unchanged
parent radioligand using high-performance liquid chromatograph analysis. The
[11C]UCB-J plasma-free fraction was measured by ultrafiltration in triplicate using
an arterial blood sample taken prior to tracer injection.
Image analysis. Processing and modelling were conducted using MIAKAT soft-
ware version 4.3.7 (http://www.miakat.org/MIAKAT2/index.html), which imple-
ments functions from MATLAB (Mathworks Inc., Natick, MA, USA), FSL (version
5.0.10; FMRIB, Oxford, UK) and Statistical and Parametric Mapping12 (SPM12,
Wellcome Trust Centre for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm).
Each subject’s MRI underwent brain extraction using FSL, and grey matter
segmentation and rigid body coregistration to a standard reference space82 using
SPM12 as implemented via MIAKAT. The template brain image and associated
Clinical Imaging Centre (CIC) atlas83 were then warped nonlinearly to the
individual subject’s MRI image where the FC, ACC and hippocampus were defined
as the primary ROIs (Supplementary Fig. 6). The CIC atlas was also used to define
the dorsolateral prefrontal cortex, temporal, parietal and occipital lobes, thalamus
and amygdala as additional ROIs for the exploratory analysis of effects in other
brain regions (Supplementary Fig. 6). The centrum semiovale ROI was generated
from the automated anatomical labelling template84 according to parameters
defined for its use as a reference region for nondisplaceable binding of [11C]UCB-
J31 (Supplementary Fig. 6).
PET images were registered to each subject’s MRI image and corrected for
motion using frame-to-frame rigid-body registration, with the 14th frame
(acquired 540–660 s into the scan) as the reference frame as this shows good
anatomical delineation. Regional time activity curves (TACs) were generated for
each ROI.
Regional TAC and arterial input function data were analysed together using the
one-tissue compartment model (1TCM), which has been shown to produce reliable
estimates of [11C]UCB-J volumes of distribution (VT)44,48.
Grey matter masks were applied to the ROIs within MIAKAT to extract both
the grey matter VT and the GMV of the ROI. For each subject, regional corrected
GMV is expressed as proportions of the subject’s own total brain volume, including
grey matter, white matter and cerebrospinal fluid, to account for intersubject
variation in total brain volume. Furthermore, regional DVR was obtained by use of
the centrum semiovale as a pseudoreference region31,48.
Animals and antipsychotic drug administration. Animal experiments were
carried out in accordance with the Home Office Animals (Scientific Procedures)
Act (1986) and European Union (EU) Directive 2010/63/EU, with the approval of
the local Animal Welfare and Ethical Review Body (AWERB) panel at King’s
College London (KCL). Male Sprague-Dawley rats (Charles River UK Ltd, Margate,
UK), initial body weight 240–270 g (6–10 weeks of age), were administered with
vehicle (β-hydroxypropylcyclodextrin, 20% wt/vol, acidified by ascorbic acid to pH
6), HAL (0.5 or 2 mg/kg/day; Sigma-Aldrich, Gillingham, UK) or OLZ (7.5 mg/kg/
day; Sigma-Aldrich, Gillingham, UK) for 28 days (~2.4 human years based on 11.8
rat days as equivalent to 1 human year64) using osmotic minipumps (Alzet Model
2ML4; 28 days; Alzet, Cupertino, CA, USA) inserted subcutaneously on the back
flank. After 28 days, animals were terminally anaesthetised by injection of sodium
pentobarbital (60 mg/kg, intraperitoneal) and culled by cardiac perfusion using
heparinised ice-cold 0.9% saline37,38. A blood sample was collected at termination
for estimation of drug levels, measured using tandem mass spectrometry (Cypro-
tex, Macclesfield, UK). Three cohorts of vehicle and drug-exposed rats were gen-
erated for different experimental end-points. Specifically, cohort 1 comprised
vehicle- (n= 10); 0.5 mg/kg/day (n= 12) or 2 mg/kg/day HAL- (n= 11) treated
groups; following perfusion, brain tissue was snap-frozen to be utilised for western
blotting or, in a subset of these animals, for [3H]UCB-J autoradiography (vehicle,
n= 7; 0.5 mg/kg/day HAL, n= 3; 2 mg/kg/day HAL, n= 5). Cohort 2 comprised
vehicle (n= 11) and 0.5 mg/kg/day HAL- (n= 11) exposed rats; brain tissue was
drop-fixed overnight in 4% PFA at 4 °C, and then cryoprotected in buffered 30%
sucrose solution for 48 h at 4 °C prior to freezing and processing for post-mortem
analysis of SV2A intensity using immunofluorescence staining and confocal
microscopy. Cohort 3 comprised vehicle- (n= 4) and 7.5 mg/kg/day OLZ- (n= 12)
exposed rats. Brain tissue was fixed and processed for immunostaining in the same
way as brain tissue from cohort 2.
Synaptosome extraction and western blotting. The frontal cortices (FC—pre-
frontal and cingulate cortex) of snap-frozen hemispheres were dissected on ice and
homogenised in lysis buffer (150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM
Tris pH 7.4, 1% Triton X-100, supplemented with a cocktail of protease and
phosphatase inhibitors (Pierce, UK)) using a plastic pestle. Total lysate was cen-
trifuged for 8 min at 2000 rpm at 4 °C to remove nuclei. The resultant supernatants
were then centrifuged for 15 min at 13,000 rpm at 4 °C. The resultant pellet con-
taining crude synaptosomes was resuspended in lysis buffer. A total of 30 μg of
protein from each sample was analysed by western blots probed with rabbit
polyclonal α-SV2A (ab32942, Abcam, Cambridge, UK; 1:2000) or mouse
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monoclonal α-GAPDH (60004-1, Protein Tech, 1:10,000) and the appropriate
secondary antibodies. Protein bands were visualised using the Biorad ChemiDoc
scanner using Image LabTM Software (PC Version 6.0 SOFT-LIT-170-9690-
ILSPC) and quantified using Image Studio (Version 5.2.5, Li-Cor Biosciences).
SV2A protein intensity was normalised to that of GAPDH as the loading control
for each rat. See Supplementary Fig. 4 for unprocessed western blot images of
SV2A and GAPDH protein levels in synaptosome fractions purified from the
rat FC.
Ex vivo autoradiography for SV2A using [3H]UCB-J. Coronal sections (20-μm-
thick) from a subset of the hemispheres from cohort 1 were thaw mounted on 1%
gelatinised superfrost slides. Individual slides containing 10–12 adjacent tissue sec-
tions at 500 μm intervals were then preincubated in assay buffer (50mM Tris Base,
140mM NaCl, 1.5 mM MgCl2, 5 mM KCl, 1.5 mM CaCl2, pH 7.4) for 10min at
room temperature (RT), and subsequently incubated for 2 h at RT in assay buffer
containing either [3H]UCB-J, a radioligand specific for SV2A85 (12.5 nM), or [3H]
UCB-J in the presence of levetiracetam (Sigma, Gillingham, UK; diluted to 1mM in
DMSO) to assess total and non-specific binding, respectively. After incubation, slides
were washed twice in ice-cold wash buffer (50mM Tris Base, 1.4 mM MgCl2, pH
7.4), followed by a brief rinse in ice-cold reverse osmosis (RO) water and dried in a
cool airstream. Sections were apposed to Carestream Kodak Biomax Light film
(Sigma-Aldrich) adjacent to tissue-equivalent tritium microscale standards (Amer-
ican Radiolabeled Chemicals) for 6 weeks before the autoradiograms were developed
and analysed using MCID Basic 7.0 software (Interfocus, Cambridge, UK).
Fluorescence immunostaining. Coronal sections (30-μm thick, interval 1/12,
360 μm spacing between sections) from one hemisphere of each animal in cohorts
2 and 3 were stained free-floating. For antigen retrieval, sections were incubated for
10–15 min in 10 mM sodium citrate (pH 6.2) at RT, followed by incubation in pre-
heated 10 mM sodium citrate (pH 6.2) in a water-bath at 78 °C. Sections were then
allowed to cool down to RT in the same solution while gently shaking for 30 min.
After a brief wash in PBS supplemented with 0.05% Triton X-100, sections were
incubated for 4 h in blocking solution (10% NGS, 1.5% BSA, 0.3% Triton X-100 in
PBS) and then overnight with primary antibody (Rabbit-α-SV2A, Abcam ab32942;
1:1000). The next day, sections were incubated for 2 h in secondary antibody
solution (Goat-α-rabbit Alexa-555, abcam ab150090; both 1:1000), mounted on
Superfrost Plus slides (Thermo Fisher), and air-dried at RT for 1 h before cover-
slipping with mounting medium containing DAPI (Vectashield).
Confocal image acquisition and analysis. Images of SV2A staining were acquired
as a stack with an interval of 0.3 μm using an Inverted Spinning Disk confocal
microscope (Nikon, JP) and a 60× oil immersion lens objective (NA 1.4). SV2A
intensity was analysed using an in-house written macro in ImageJ (https://imagej.
net/Welcome). Total SV2A staining intensities were measured from three con-
secutive optical sections within each image stack, selected based on quality of
staining and contrast in the image, to ensure proper synaptic staining. These
optical sections were then combined by maximum intensity projection. Total SV2A
intensity was measured after background subtraction using a rolling ball with
radius of 25 pixels (5 μm) to remove diffuse (and presumably non-synaptic)
staining.
See Supplementary methods for further information.
Statistical analysis of [11C]UCB-J PET data. Statistical analyses were performed
using GraphPad Prism version 8.00 for Mac (GraphPad Software, La Jolla, Cali-
fornia, USA, (www.graphpad.com)), IBM SPSS Statistics, Version 25, and RStudio
Version 1.1.456 (RStudio Team (2016), RStudio, Inc., Boston, MA (http://www.
rstudio.com/)). We tested for normality of distribution using the Shapiro–Wilk
test. A two-way analysis of variance (ANOVA) was used to test the effects of group
and ROI, and group-by-ROI interactions, on [11C]UCB-J VT and to explore if
differences in corrected GMV contributed to our VT findings. Where there were
significant effects, planned post-hoc independent samples t-tests (two-tailed) were
used to test the effect of group on VT and corrected GMV at each ROI. For post-
hoc analyses, an FDR (Q) of 5% was used to limit false discoveries when per-
forming multiple comparisons between groups in the three ROIs86 and FDR-
adjusted p values are reported. Group differences in clinico-demographic variables
were assessed using independent sample t-tests for normally distributed data,
Fisher’s test for categorical data and Kolmogorov–Smirnov tests for nonparametric
data. We tested if there were significant associations between grey matter SV2A
levels and GMV, PANSS scores, antipsychotic dose and duration of illness using
the Pearson product-moment correlation coefficient for normally distributed data,
and Spearman’s rank correlation for non-normally distributed data. The rela-
tionship with antipsychotic dose was explored using chlorpromazine-equivalents
derived using the defined daily doses (DDD) method87.
We conducted an exploratory analysis of other brain regions to assess whether
there were significant alterations in [11C]UCB-J VT in other brain regions and in
[11C]UCB-J DVR in schizophrenia using two-way ANOVA with planned post-hoc
independent samples t-tests with FDR correction for multiple comparisons.
Statistical analyses of animal data. Statistical analyses were performed using
Prism version 8.0.0 (GraphPad Software, La Jolla, California, USA). Data were
tested for a normal distribution using the Shapiro-Wilk test. Western blot data
were analysed using non-parametric Kruskal–Wallis test, with α= 0.05. Auto-
radiography and SV2A immunostaining data were analysed by two-way ANOVA
with Bonferroni’s post-hoc test. Researchers were blinded to the treatment groups
for all analyses.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The imaging and related clinical data have been deposited on the NODE PET
data repository (listed as SV2A imaging in schizophrenia) and are available at:
https://molecular-neuroimaging.com/neuroimaging-database/.
Code availability
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request.
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